GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seelos Therapeutics Inc (OTCPK:SEELQ) » Definitions » FCF Yield %

SEELQ (Seelos Therapeutics) FCF Yield % : -7,762.57 (As of Dec. 15, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Seelos Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Seelos Therapeutics's Trailing 12-Month Free Cash Flow is $-13.27 Mil, and Market Cap is $0.17 Mil. Therefore, Seelos Therapeutics's FCF Yield % for today is -7,762.57%.

The historical rank and industry rank for Seelos Therapeutics's FCF Yield % or its related term are showing as below:

SEELQ' s FCF Yield % Range Over the Past 10 Years
Min: -80081355.93   Med: -2716.17   Max: -21.87
Current: -7762.57


During the past 13 years, the highest FCF Yield % of Seelos Therapeutics was -21.87%. The lowest was -80081355.93%. And the median was -2716.17%.

SEELQ's FCF Yield % is ranked worse than
99.73% of 1507 companies
in the Biotechnology industry
Industry Median: -12.96 vs SEELQ: -7762.57

Seelos Therapeutics's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.


Seelos Therapeutics FCF Yield % Historical Data

The historical data trend for Seelos Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seelos Therapeutics FCF Yield % Chart

Seelos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.29 -24.27 -28.50 -84.65 -175.64

Seelos Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.91 -78.35 -56.15 -205.93 -196.04

Competitive Comparison of Seelos Therapeutics's FCF Yield %

For the Biotechnology subindustry, Seelos Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seelos Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Seelos Therapeutics's FCF Yield % falls into.



Seelos Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Seelos Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-23.912 / 13.6144384
=-175.64%

Seelos Therapeutics's annualized FCF Yield % for the quarter that ended in Jun. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.972 * 4 / 1.98328176
=-196.04%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Seelos Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Seelos Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Seelos Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Seelos Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
300 Park Avenue, 2nd Floor, New York, NY, USA, 10022
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.
Executives
Raj Mehra director, officer: See Remarks C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Michael Joseph Golembiewski officer: Chief Financial Officer 7 TURTLE CT, FLEMINGTON NJ 08822
Daniel J. O'connor director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Judith Dunn director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Brian Lian director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Neil Morton officer: SVP, Chief Business Officer C/O APRICUS BIOSCIENCES, INC., 11975 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Richard W Pascoe director, officer: CEO & Secretary C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Sarissa Capital Domestic Fund Lp 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830